Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 7 Breast 7 Gynecologic 4 Gastrointestinal 4 Tumor-Agnostic 3 Sarcoma 2 Other hematologic neoplasm 2 Thoracic 1 Plasma cell 1 NET 1 Myeloid 1 Lymphoid 1 Endocrine 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 15 Magnetic Resonance Spectroscopy 9 Everolimus 8 gallium Ga 68 dotatate 6 lanreotide 4 cabozantinib 4 Temozolomide 4 Specimen Handling 4 Nivolumab 4 Lutetium-177 4 Lutetium 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 surufatinib 3 olaparib 3 copper dotatate CU-64 3 Somatostatin 3 Injections 3 Ga(III)-DOTATOC 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 Capecitabine 3 pembrolizumab 2 fludarabine phosphate 2 fludarabine 2 amino-acid, glucose, and electrolyte solution 2 X-Rays 2 Sunitinib 2 Radiosurgery 2 Octreotide 2 Drug Therapy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × talazoparib × NET × Clear all

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡